Back to School: How biopharma can reboot drug development. Access exclusive analysis here

BioDelivery, QLT deal

BDSI exercised an option to acquire U.S. rights to QLT's BEMA drug

Read the full 127 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE